Diabetic Nephropathy Market Poised To Register Healthy Expansion in Upcoming Years
Added: (Fri Mar 08 2019)
Pressbox (Press Release) -
Diabetes is a lifelong, chronic disease caused by excessive levels of glucose in the blood primarily due to lack or insufficiency of insulin hormone to metabolize the glucose in the blood. This accumulated glucose in the blood does not reach body cells and severely affects multiple organs such as kidneys, eyes, nerves, blood vessels, and heart. Diabetic nephropathy is one of the common diabetic kidney diseases characterized by the presence of proteinuria>0.5 g/24 h, reduction in glomerular filtration rate, and high blood pressure. Obesity, hypertension, high lipid, and high blood glucose levels due to diabetes can damage the part of kidney which filters blood and is associated with increased cardiovascular mortality. If left untreated, it could lead to chronic kidney disease or failure. Diabetic nephropathy can develop in any individual suffering from type 1 or type 2 diabetes. This disease is the leading cause of kidney failure across the globe.
Read Report Overview: https://www.transparencymarketresearch.com/diabetic-nephropathy-market.html
Rise in prevalence of diabetes across the globe is anticipated to drive the diabetic nephropathy market. According to the National Center for Biotechnology Information, 126 million people were affected by diabetic nephropathy in 2010; more than 191 million people are likely to be affected by diabetic nephropathy by 2030. According to the U.S. National Health and Nutrition Examination Survey (NHANES) 2009 to 2014, prevalence of diabetic nephropathy was 26.2% among adults with diabetes, taken into account albuminuria persistence. Increase in geriatric population, high prevalence of obesity, and rise in sedentary lifestyle are the key factors propelling the global diabetic nephropathy market. Furthermore, increase in awareness about the early detection of diabetic nephropathy among diabetic patients across the globe, improvement in health care facilities in emerging and developed countries, and availability of multiple treatment options with advanced technology augment the market. However, negligence toward diabetic nephropathy, poor planning of diabetic nephropathy treatment in low income countries, and lack of skilled professionals for treatment of diabetic nephropathy in emerging and less developed countries are the key factors restraining the market.
The global diabetic nephropathy market can be segmented based on indication, type of treatment, diagnosis type, end-user, and region. In terms of indication, the market can be bifurcated into type-1 diabetes and type-2 diabetes. Based on type of treatment, the global diabetic nephropathy market can be classified into diuretics, antioxidant inflammation modulator, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors), renin inhibitors, calcium channel blockers, and others (G protein-coupled receptors and monocyte chemoattractant protein-1). The ACE inhibitors segment held major share of the global diabetic nephropathy market in 2017. This is attributed to safety and efficacy for specific symptoms related to diabetic nephropathy. In terms of diagnosis type, the market can be categorized into imaging tests, renal function testing, urine test, blood test, and renal biopsy. Based on end-user, the global diabetic nephropathy market can be divided into hospitals, clinics, diagnostic centers, and research institutes. Most of the pipeline drugs for diabetic nephropathy are in the pre-clinical stage of development and phase II stage of development. The pipeline drugs for diabetic nephropathy consist of nearly 68 drug candidates in different stages of development.
Request for the Brochure of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=54729
In terms of region, the global diabetic nephropathy market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market during the forecast period owing to rise in prevalence of diabetic nephropathy, well-established health care infrastructure, and increase in awareness about diabetic nephropathy among diabetic patients. Asia Pacific is anticipated to be the second leading market for diabetic nephropathy treatment due to increase in diabetic population and changing lifestyles of people. The market in Asia Pacific is expected to expand at the highest CAGR during the forecast period. Middle East & Africa is likely to be the least attractive market primarily due to the presence of low income groups, lack of skilled personnel, and poor access to health care facilities.
Key players operating in the global diabetic nephropathy market are AstraZeneca plc, Bayer AG, Novartis AG., Allergan, Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Gilead Sciences, Inc., Johnson & Johnson, Novo Nordisk AS, Regeneron Pharmaceuticals, Inc., and Merck & Co, Inc. New business development through acquisitions & mergers, and establishment of subsidiaries in emerging economies are the common trends in the global diabetic nephropathy market.
Request for Discount on the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=54729
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453